Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 vs salmeterol + fluticasone in moderate-to-severe COPD (China)
CTR20131698Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Sep 2014; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20131698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131698.